View:
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 30, 2006
SANGAMO BIOSCIENCES, INC.
------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware
----------------------------------------------
(State or Other Jurisdiction of Incorporation)
000-30171 68-0359556
------------------------ ---------------------------------
(Commission File Number) (IRS Employer Identification No.)
501 Canal Blvd, Suite A100 Richmond, California 94804
----------------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
(510) 970-6000
----------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On October 30, 2006, Sangamo BioSciences, Inc. issued a press release
reporting that the shares used in computing the basic and diluted net loss per
common share for the third quarter ended September 30, 2006 were incorrect. As a
result, the basic and diluted net loss per common share was incorrectly stated
as $0.09 per share and should have been stated as $0.08 per share. A copy of the
press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits. The following material is filed as an exhibit to this Current
Report on Form 8-K:
Exhibit No.
- -----------
99.1 Press Release Issued October 30, 2006.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DATE: October 31, 2006
SANGAMO BIOSCIENCES, INC.
By: /s/ EDWARD O. LANPHIER II
----------------------------------
Edward O. Lanphier II
President, Chief Executive Officer
Exhibit 99.1
SANGAMO BIOSCIENCES, INC.
Point Richmond Tech Center
501 Canal Boulevard
Richmond, CA 94804
510-970-6000 o 510-236-8951(Fax)
- --------------------------------------------------------------------------------
SANGAMO BIOSCIENCES CORRECTS THIRD QUARTER 2006 FINANCIAL RESULTS
NET LOSS PER SHARE IMPROVES FROM $0.09 TO $0.08
Richmond, Calif. - October 30, 2006 - Sangamo BioSciences, Inc. (Nasdaq: SGMO)
today reported the shares used in computing the basic and diluted net loss per
common share for the third quarter ended September 30, 2006 were incorrect. As a
result, the basic and diluted net loss per common share was incorrectly stated
as $0.09 per share and should have been stated as $0.08 per share. Set forth
below is a complete corrected Selected Financial Data schedule for the three and
nine month periods ended September 30, 2006.
SELECTED FINANCIAL DATA
(in thousands, except per share data)
(unaudited)